Latest news with #DHR
Yahoo
a day ago
- Business
- Yahoo
Danaher (DHR) Reports Q2: Everything You Need To Know Ahead Of Earnings
Diversified science and technology company Danaher (NYSE:DHR) will be reporting earnings this Tuesday before market hours. Here's what to look for. Danaher beat analysts' revenue expectations by 2.7% last quarter, reporting revenues of $5.74 billion, flat year on year. It was a very strong quarter for the company, with an impressive beat of analysts' organic revenue estimates and an impressive beat of analysts' EPS estimates. Is Danaher a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Danaher's revenue to grow 1.7% year on year to $5.84 billion, a reversal from the 2.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.64 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Danaher has missed Wall Street's revenue estimates twice over the last two years. With Danaher being the first among its peers to report earnings this season, we don't have anywhere else to look to get a hint at how this quarter will unravel for life sciences tools & services stocks. However, the whole sector has been hit hard over the last month as stocks in Danaher's peer group are down 2.3% on average. Danaher is down 3% during the same time and is heading into earnings with an average analyst price target of $248.53 (compared to the current share price of $190.53). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
4 days ago
- Business
- Globe and Mail
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
Danaher Corporation DHR is scheduled to release second-quarter 2025 results on July 22, before market open. The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates an increase of 1.6% from the year-ago quarter's figure. The consensus mark for earnings is pinned at $1.64 per share, which has remained steady in the past 30 days. The estimate indicates a decrease of 4.7% from the figure reported in the year-ago quarter. The company's bottom line surpassed the Zacks Consensus Estimate in three of the preceding four quarters while missing the mark in one, the average beat being 8.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Let's see how things have shaped up for Danaher this earnings season. Key Factors and Estimates for Q2 Weakness in Danaher's protein consumables, flow cytometry and lab automation solutions businesses, due to lower demand across academic and government end-markets, is likely to have hurt the Life Sciences segment's revenues in the second quarter. Also, sales decline in the filtration business due to soft demand in the energy-related end market is likely to have impacted the segment's performance. We expect the segment's revenues to decrease 3.4% from the year-ago quarter to $1.71 billion. DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. For the quarter under review, we anticipate SG&A expenses to be $1.55 billion, indicating a 5.8% increase from the year-earlier level. The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability. However, strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe and Southeast Asia, is expected to have aided the Biotechnology segment. The segment's performance is also likely to have benefited from solid momentum in the discovery and medical business. We expect the segment's revenues to increase 7% from the year-ago quarter to $1.83 billion. Solid momentum in the pathology and acute care diagnostics businesses is expected to drive the Diagnostics segment's results. We expect the segment's revenues to increase 1.1% from the year-ago quarter to $2.29 billion. Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped the company solve some pertinent healthcare challenges. Earnings Whispers Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below. Earnings ESP: DHR has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.64 per share. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Zacks Rank: DHR presently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Stocks to Consider Here are some companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2025 results on July 31. CVS Health's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 18.1%. Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2025 results on Aug. 6. Cencora's earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 6%. Amgen Inc. AMGN has an Earnings ESP of +0.07% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2025 results on Aug. 5. Amgen's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.3%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
Time of India
04-07-2025
- Entertainment
- Time of India
DHR celebrates its 144th birthday as ‘Toy Train Day'
Darjeeling : The Darjeeling Himalayan Railway (DHR) celebrated its 144th birthday on Friday as the first 'Toy Train Day', marking the occasion with tributes to the rich past of the heritage marvel and promises of a dynamic future. To commemorate the very day its first locomotive ascended the misty hills from Siliguri to Darjeeling in 1881, celebrations were held at Sukna station, about 9 km from Siliguri. DHR director Rishav Choudhary said: "As part of the 144th anniversary, we are not only celebrating the past but preparing for the future, aiming to cater to the growing interest in heritage travel and strengthen Darjeeling's appeal as a year-round destination." You Can Also Check: Kolkata AQI | Weather in Kolkata | Bank Holidays in Kolkata | Public Holidays in Kolkata To enhance tourist experience and operational capacity, DHR is set to roll out a range of new services — including evening joy rides, on-demand charter services and additional routes from Sukna station. Three new diesel locomotives are also being introduced to the fleet by the end of 2025. Choudhary said DHR had received one loco and it was undergoing trials. Two more are expected later this year, with all three being manufactured by San Engineering in Bengaluru and Hyderabad. "New locomotives will be pressed into service from next month. We will also introduce new services from Sukna soon," he added. On Friday, DHR, in collaboration with North Bengal Painters Association, hosted a variety of art competitions for children, including sit-and-draw, painting and poster-making events. "The goal is to inspire the youth to connect with the Hills and this historic railway through art," Choudhary said. Unesco included DHR on the list of World Heritage Monuments on Dec 5, 1999. DHR covers 87.21 km of journey in 7 hours and 20 minutes, climbing more than 2,000 metres into the mountains covering 12 stations. It also runs 8 km short joy rides between Darjeeling and Ghoom through Batasia Loop.
New Indian Express
04-07-2025
- Entertainment
- New Indian Express
Darjeeling toy train celebrates 144th birthday
KOLKATA: The iconic toy train of Darjeeling, a timeless favourite among tourists visiting the hill station, celebrated its 144th birthday on July 4 with the first-ever 'Toy Train Day'. Despite a few recent accidents, the train continues to captivate visitors with its slow, scenic journey along the mountain slopes. The celebration, organised jointly by the Darjeeling Himalayan Railway (DHR) and the North Bengal Painters' Association, was held at Sukna Railway Station near Siliguri. The DHR, which holds UNESCO World Heritage status, marked the day with a series of events and competitions themed around the toy train. Activities such as a 'Sit and Draw' competition, poster making, live art, and a picture exhibition were held, with participation from several local kindergarten students. The event aimed to foster a deeper connection between the community and the historic railway, while also boosting tourism in the region.
Yahoo
01-07-2025
- Business
- Yahoo
Danaher's Quarterly Earnings Preview: What You Need to Know
Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $142.3 billion by market cap. The leading global life sciences and diagnostics innovator is expected to announce its fiscal second-quarter earnings for 2025before the market opens on Tuesday, Jul. 22. Ahead of the event, analysts expect DHR to report a profit of $1.64 per share on a diluted basis, down 4.7% from $1.72 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. Jeff Bezos Unloads $5.4B in Amazon Shares: Should You Buy or Sell AMZN Stock Now? Elon Musk's Tesla Makes History With 'First Time That a Car Has Delivered Itself to Its Owner' This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! For the full year, analysts expect DHR to report EPS of $7.70, up 2.9% from $7.48 in fiscal 2024. Its EPS is expected to rise 11.4% year over year to $8.58 in fiscal 2026. DHR stock has underperformed the S&P 500 Index's ($SPX) 13.6% gains over the past 52 weeks, with shares down 20.9% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund's (XLV) 7.5% dip over the same time frame. On Apr. 22, DHR shares closed up more than 3% after reporting its Q1 results. Its adjusted EPS of $1.88 surpassed Wall Street expectations of $1.62. The company's revenue was $5.7 billion, topping Wall Street forecasts of $5.6 billion. DHR expects full-year adjusted EPS in the range of $7.60 to $7.75. Analysts' consensus opinion on DHR stock is bullish, with a 'Strong Buy' rating overall. Out of 23 analysts covering the stock, 18 advise a 'Strong Buy' rating, one suggests a 'Moderate Buy,' and four give a 'Hold.' DHR's average analyst price target is $243, indicating a potential upside of 23% from the current levels. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
